VERU INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
VERU INC. (VERU) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.80% for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-12-17
- VERU INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.80%.
- VERU INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 0.00%.
- VERU INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.30%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2025-09-30 | -0.80% 10-K · filed 2025-12-17 | |
| 2024-09-30 | 0.00% 10-K · filed 2025-12-17 | -0.50% 10-K · filed 2024-12-16 |
| 2023-09-30 | -0.30% 10-K · filed 2024-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |